Skip to Content

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PA-07-356: Clinical Cancer Therapy and Prevention Research (R01)

    The National Cancer Institute (NCI) is seeking research project (R01) applications to conduct translational, clinical, therapeutic, and preventive studies and trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists to translate insights in cancer genetics, cancer epigenetics, and cancer biology, coupled with the development of new anti-cancer agents, into innovative cancer intervention studies and trials. The overall aims of this funding opportunity announcement (FOA) are two-fold: (1) to stimulate the development of innovative cancer prevention and therapy clinical trials with or without laboratory correlative studies; and (2) to support innovative correlative laboratory studies retrospectively and prospectively linked to therapeutic/preventive clinical trials. Investigators may address either aim in their applications.

    • No set-aside

    See full description in NIH Guide: PA-07-356

  • PA-07-041 and PA-07-042: Image-Guided Cancer Interventions (STTR [R41/R42] & SBIR [R43/R44])

    • Release Date: February 20, 2007
    • Application Receipt Date: Multiple dates, see announcements.
    • Contacts:

      Keyvan Farahani, Ph.D. (, Phone: 301-496-9531
      Laurence P. Clarke, Ph.D. (, Phone: 301-435-9190

    These Funding Opportunity Announcements (FOA) support the development and clinical validation of systems for image-guided interventions (IGIs) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; the validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multisite clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

    See full description in NIH Guide: STTR (R41/R42) PA-07-041; SBIR (R43/44) PA-07-042

  • Academic-Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations (R01) (PAR-10-169)

    • Release Date: February 12, 2007
    • Application Receipt Date: Multiple dates, see announcement.
    • Expiration Date: May 8, 2013
    • Contacts:

      Houston Baker, Ph.D., Tel 240-276-5908, e-mail
      James Deye, Ph.D., Tel 240-276-5705, e-mail

    This Funding Opportunity Announcement (FOA) issued by the Cancer Imaging and Radiation Research Programs of the National Cancer Institute (NCI), National Institutes of Health (NIH), encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either animal or human in vivo imaging, image guided, and/or spectroscopic systems and methods designed to solve targeted cancer problems for cancer research, clinical trials, and/or clinical practice. The partners on each application will establish an inter-disciplinary, multi-institutional research team to work in a strategic alliance to implement a coherent strategy to develop and translate the proposed system or methods with potential for significant impact on preclinical, single, or multisite clinical studies. Partnerships must include at least one lead academic and one lead industrial organization large or small among their numbers. For either preclinical or clinical research, funding may be requested for limited additional copies of prototype systems and methods in order to optimize and validate them across different platforms and/or research sites. Each partnership is encouraged to plan to solve its choice of targeted cancer problem within the five year funding period. This FOA supports clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. It will not support commercial production.

    Note that this revised PAR has provided: (a) a revised definition of translational research consistent with the NCI Translational Research Working Group (TRWG) recommendations, (b) a definition of innovation within the context of the TRWG recommendation, (c) examples of translational research for current commercial and next generation of imaging platforms and (d) modified review criteria within the context of the TRWG recommendations. The intent of the revised PAR is to encourage applications with a strong translational research focus. Note that investigators interested in the creation of research resources to assist in validation of imaging technologies are encouraged to explore collaboration with research networks (U01, U54) consistent with the PAR goals.

    See NIH Guide Announcement